Edition:
United Kingdom

People: Alexion Pharmaceuticals Inc (ALXN.OQ)

ALXN.OQ on NASDAQ Stock Exchange Global Select Market

108.54USD
16 Sep 2019
Change (% chg)

$1.14 (+1.06%)
Prev Close
$107.40
Open
$106.66
Day's High
$109.42
Day's Low
$106.63
Volume
808,649
Avg. Vol
706,283
52-wk High
$141.81
52-wk Low
$92.57

Rummelt, Andreas 

Dr. Andreas Rummelt, Ph.D., is Independent Director of Alexion Pharmaceuticals, Inc. He has served as the Chief Executive Officer of InterPharmaLink AG, a management consulting firm focused on advising companies in the healthcare industry, since January 2011. From December 2008 until January 2010, Dr. Rummelt was Group Head of Quality Assurance and Technical Operations at Novartis. He had been a member of the Executive Committee of Novartis from January 2006 until his resignation in January 2010. He joined Sandoz Pharma Ltd. in 1985 and held various positions of increasing responsibility in pharma development. In 1994, he was appointed Head of Worldwide Technical Research and Development, a position he retained following the merger that created Novartis in 1996. From 1999 to 2004, Dr. Rummelt served as Head of Technical Operations of the Novartis Pharmaceuticals Division and from 2004 to 2008 as Global CEO of Sandoz. Dr. Rummelt graduated with a Ph.D. in pharmaceutical sciences from the University of Erlangen-Nuernberg, Germany.

Basic Compensation

Total Annual Compensation, USD 95,000
Restricted Stock Award, USD 253,858
Long-Term Incentive Plans, USD --
All Other, USD --
Fiscal Year Total, USD 348,858

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

David Brennan

448,858

Ludwig Hantson

16,490,200

Paul Clancy

5,486,510

Indrani Franchini

--

Ellen Chiniara

--

Anne-Marie Law

5,296,490
As Of  31 Dec 2018